HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZCMD
Zhongchao Inc.
There isn't enough reported data to score ZCMD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZCMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ZCMD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZCMD PE Valuation
ZCMD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZCMD Forward outlook
There aren't enough analyst estimates for ZCMD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$178.56 | +$6,300.19 |
| Q2 2024 | -$3,755.71 | +$604.13 |
| Q4 2023 | -$6,478.75 | -$4,797.31 |
| Q2 2023 | -$4,359.84 | -$3,904.65 |
| Q4 2022 | -$1,681.44 | -1301% |
| Q4 2021 | $140.01 | -95% |
| Q4 2020 | $2,723.04 | -2.1% |
ZCMD has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ZCMD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ZCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.8M | -23% |
| Q2 2025 | $5.6M | -33% |
| Q4 2024 | $7.5M | -17% |
| Q2 2024 | $8.3M | -20% |
| Q4 2023 | $9.1M | +32% |
| Q2 2023 | $10.4M | +42% |
| Q4 2022 | $6.9M | -11% |
| Q2 2022 | $7.3M | -15% |
ZCMD's revenue has slid since its 2020 peak: $6M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -92% | -12 points |
| Q2 2025 | -16% | +42 points |
| Q4 2024 | -3.9% | +39 points |
| Q2 2024 | -0.6% | -5.8 points |
| Q4 2023 | -80% | -65 points |
| Q2 2023 | -58% | -70 points |
| Q4 2022 | -43% | -70 points |
| Q2 2022 | 5.2% | -24 points |
ZCMD's operating margin was −92% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ZCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$3.2M | -399% |
| Q2 2024 | -$1.3M | +$579.7K |
| Q4 2023 | $1.1M | +$2.5M |
| Q2 2023 | -$1.9M | -$1M |
| Q4 2022 | -$1.5M | -210% |
| Q2 2022 | -$821.9K | -$561.4K |
| Q4 2021 | $1.3M | +$2.5M |
| Q4 2020 | -$1.2M | -1360% |
ZCMD has burned cash in most quarters: −$5M over the past year, against −$1M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ZCMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +22 shares |
| 1 year | +1.5% | +26 shares |
ZCMD has 1,772 diluted shares, up 1.5% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZCMD Net Leverage
ZCMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.0 | Oversold |
| Stochastic | 3.0 | Oversold |
ZCMD's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZCMD PE vs Healthcare Sector
| Metric | ZCMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ZCMD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ZCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.35 | 31% below |
| 20 week MA | $1.90 | 51% below |
| 50 week MA | $251.7 | 100% below |
| 100 week MA | $981.6 | 100% below |
| 200 week MA | $5,187.8 | 100% below |
ZCMD is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ZCMD on returns for 2026, with the stronger performance.
ZCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58,180.8 | $26,188.8 | -55% |
| 2021 | $26,188.8 | $27,081.6 | +3.4% |
| 2022 | $27,081.6 | $17,260.8 | -36% |
| 2023 | $17,260.8 | $5,224.4 | -70% |
| 2024 | $5,224.4 | $2,455.2 | -53% |
| 2025 | $2,455.2 | $757.4 | -69% |
| 2026 YTD | $757.4 | $0.93 | -100% |
ZCMD has finished four years in a row lower, and it's down 100% so far in 2026.